📊 CHRS Key Takeaways
Investment Thesis
Coherus Oncology exhibits severe operational distress with massive negative operating margins (-429.5%) and substantial operating cash burn (-$138.5M) that cannot be sustained despite modest revenue growth of 59.8% YoY. The company's positive net income and ROE metrics are likely distorted by non-cash items or significant one-time gains that mask underlying operational deterioration, indicating fundamental business performance remains deeply negative.
CHRS Strengths
- Strong revenue growth of 59.8% year-over-year demonstrates market demand for products
- Positive gross margin of 275.2% suggests strong pricing power on products sold
- Adequate liquidity with $88.9M cash and 1.47x current ratio provides near-term runway
CHRS Risks
- Severe operating losses of $181.1M with negative operating margin of -429.5% indicating unsustainable business model
- Massive negative operating cash flow of -$138.5M and negative free cash flow of -$138.8M will deplete cash reserves quickly
- Debt/Equity ratio of 1.21x with negative interest coverage ratio of -20.1x indicates inability to service debt from operations, creating financial distress risk
- Disconnect between reported positive net income ($168.0M) and negative operating cash flow suggests reliance on non-recurring items or accounting adjustments rather than genuine profitability
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Operating margin improvement trajectory toward sustainability
- Quarterly revenue growth sustainability and gross margin stability
- Cash burn rate and runway remaining at current consumption levels
CHRS Financial Metrics
💡 AI Analyst Insight
Coherus Oncology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CHRS Profitability Ratios
CHRS vs Healthcare Sector
How Coherus Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CHRS Balance Sheet & Liquidity
CHRS 5-Year Financial Trend
5-Year Trend Summary: Coherus Oncology, Inc.'s revenue has declined by 91% over the 5-year period, indicating business contraction. The most recent EPS of $0.25 reflects profitable operations.
CHRS Growth Metrics (YoY)
CHRS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.1M | -$10.8M | $-0.09 |
| Q2 2025 | $10.3M | -$12.9M | $-0.11 |
| Q1 2025 | $2.3M | -$56.6M | $-0.49 |
| Q3 2024 | $70.8M | -$10.8M | $-0.09 |
| Q2 2024 | $58.7M | -$12.9M | $-0.11 |
| Q1 2024 | $32.4M | -$75.7M | $0.83 |
| Q3 2023 | $45.4M | -$39.6M | $-0.41 |
| Q2 2023 | $58.7M | -$42.9M | $-0.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CHRS Capital Allocation
CHRS SEC Filings
Access official SEC EDGAR filings for Coherus Oncology, Inc. (CIK: 0001512762)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CHRS
What is the AI rating for CHRS?
Coherus Oncology, Inc. (CHRS) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CHRS's key strengths?
Strong revenue growth of 59.8% year-over-year demonstrates market demand for products. Positive gross margin of 275.2% suggests strong pricing power on products sold.
What are the risks of investing in CHRS?
Severe operating losses of $181.1M with negative operating margin of -429.5% indicating unsustainable business model. Massive negative operating cash flow of -$138.5M and negative free cash flow of -$138.8M will deplete cash reserves quickly.
What is CHRS's revenue and growth?
Coherus Oncology, Inc. reported revenue of $42.2M.
Does CHRS pay dividends?
Coherus Oncology, Inc. does not currently pay dividends.
Where can I find CHRS SEC filings?
Official SEC filings for Coherus Oncology, Inc. (CIK: 0001512762) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CHRS's EPS?
Coherus Oncology, Inc. has a diluted EPS of $1.43.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.